Hao Zhang, PhD, MBA’s Post

As digital measurement technology continues to evolve, we must understand how and where #digitalendpoints add value to clinical trials.

Digital measures provide the clinical trials community with unprecedented insights into people’s true lived experiences and advance our comprehension of so many indications. Why, then, have we not deployed digital endpoints at scale? To unlock the true potential of digital endpoints in clinical trials, DiMe partnered with the Tufts Center for the Study of Drug Development and industry leaders at Johnson & Johnson, Roche, Genentech, UCB Bayer, Takeda, and MindMed to assess the net financial benefits of employing them, and our research produced fascinating data. The findings showcase evidence of significant cost reductions and financial benefits tied to leveraging digital endpoints in trials. We must continue to advance the use of digital endpoints to speed medical product development. 📰 Read the full paper here: https://lnkd.in/e9dTMgfA

Entering new territory for digital health technologies by quantifying the economic value. Promising first results from a very effective collaboration, looking forward to continuing the work! 🙏Upinder Grewal for planting the seed and bringing us together. #digitaltransformation #digitalhealth #strongertogether

Counting down to our next Journal Club on Jan. 18 at 11 a.m. ET! We're thrilled to host a panel of industry leaders from Regeneron, Bayer, Genentech, Amgen, Johnson & Johnson, Biogen, and Digital Medicine Society (DiMe). This discussion will focus on “Incorporating Digitally Derived Endpoints within Clinical Development Programs by Leveraging Prior Work”. 📰 Check out the article we'll be discussing to dive deeper: https://lnkd.in/eNykCPYH In the manuscript, the authors discuss how to incorporate a #digital health technology and digitally derived endpoint within a #clinical development program, and how to leverage prior work to demonstrate they are fit for purpose to support a new drug marketing application. 🔗 Reserve your spot today and be part of this insightful conversation: https://bit.ly/3NomRDP

🔍 Digital measures provide the #clinicaltrials community with unparalleled insights into real-life #patient experiences, enhancing our understanding of various conditions. Despite this, digital endpoints have yet to be widely implemented in clinical trials. 📊 Findings from our collaboration with Tufts Center for the Study of Drug Development, Johnson & Johnson, Roche, Genentech, UCB, Bayer, Takeda, and MindMed recently published in the Journal of Clinical & Translational Science and highlight significant cost reductions and financial benefits from digital endpoints. 🔑 The key takeaways: ▪️ Digital endpoints significantly shorten trial phases and permit smaller trial enrollment sizes ▪️ For phase 2 trials, the increase in eNPV varied from $2.1 million to $3.3 million, with ROIs between 30% to 48% per indication ▪️ The net benefits were substantially higher for phase 3 trials, with the increase in eNPV varying from $24 million to $40 million, with ROIs that were four to six times the investment 🏥 To put it simply: Digital endpoints improve patient experiences by providing faster access to treatments and real-time, personalized care through enhanced monitoring. 🔗 If you are interested in our findings, you can read them here: https://lnkd.in/gS3MzqiJ

Our recent webinar Enhancing Biopharma's Path-to-Market is now available to watch on demand. Hear from Jacqueline Barendregt, COO of IDEA Pharma | From R&D to RxD and our CEO Aiden Flynn who discuss the concept of design-thinking path-to-market strategies, which are increasingly being recognised as pivotal in the biopharma sector. Key takeaways include: 💡 Design-Thinking Path-to-Market Strategies: Learn how to integrate these strategies with advanced analytics and simulation for better decision-making. 📊 Case Studies: Discover how innovative solutions have driven clinical milestones, including an Alzheimer's trial. 🛠️ KerusCloud Demonstration: See how this platform can streamline trials, reduce costs, and improve success rates. Watch on demand below: https://lnkd.in/gUdJVAMZ #Biopharma #ClinicalSuccess #MarketStrategy #InnovativeTherapies #Webinar #ResearchandDevelopment #biotech #Pharma

📊 𝗗𝗶𝘃𝗲 𝗶𝗻𝘁𝗼 𝘁𝗵𝗲 𝗹𝗮𝘁𝗲𝘀𝘁 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗶𝗻𝗱𝘂𝘀𝘁𝗿𝘆 𝗶𝗻𝘀𝗶𝗴𝗵𝘁𝘀 Pharma and Biotech companies highlight their concerns working with large CROs, as revealed by a recent survey. Swipe left to explore key findings shedding light on the evolving landscape of sponsor and CRO partnerships. For more details, visit Clinical Trials Arena article: https://lnkd.in/dNBBydhi #ClinicalResearch #BiotechInnovation #IndustryInsights

I am looking forward to facilitating a conversation about the evolution of clinical trial quality at SCOPE Europe in Barcelona with three executives with decades of experience: Coleen Glessner, Kristine Koontz, PhD, MBA, and Shyard Wong. We'll delve into pivotal past milestones and reflect on current paradigms shaping our industry’s approach to quality management. Technological advancements have impacted every aspect of clinical trial execution; we will discuss their impact on quality and cover such topics as AI, big data, and Real World Evidence and how they will alter the way we think about the future of clinical trial quality. Thanks to Micah Lieberman for inviting me to lead this important discussion.   #ClinicalResearch #SCOPEsummit #ClinicalTrialQuality #DecentralizedTrials Diligent Pharma, Sanofi, Emergent BioSolutions, Daiichi Sankyo US

In this episode of “Transforming Biopharma,” we explore how pharma companies can build deep, collaborative partnerships with clinical trial sites to drive success. Maria Whitman talks with Lauren Wall of the University of Chicago and Caroline Smith of Charter Research about the importance of patient-centric trial design, investing in site engagement and understanding site challenges to improve the clinical trial process. #ClinicalTrials #PatientCentricity #Biopharma #ZSpodcast

In this episode of “Transforming Biopharma,” we explore how pharma companies can build deep, collaborative partnerships with clinical trial sites to drive success. Maria Whitman talks with Lauren Wall of the University of Chicago and Caroline Smith of Charter Research about the importance of patient-centric trial design, investing in site engagement and understanding site challenges to improve the clinical trial process. #ClinicalTrials #PatientCentricity #Biopharma #ZSpodcast